NCT05651022 - Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions

Solid Tumor, AdultHCC - Hepatocellular CarcinomaCRC (Colorectal Cancer)Pancreatic AdenocarcinomaNSCLC Non-small Cell Lung CancerSquamous Cell Cancer of the Head and NeckUC (Urothelial Cancer)MSI-H Cancer

Interventions

DRUG

Decoy20

Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

DRUG

Tislelizumab

Tislelizumab is a PD-1 inhibitor.

Trial Locations (12)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

29605

RECRUITING

Prisma Health Cancer Institute-ITOR, Greenville

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

44106

RECRUITING

UH Seidman Cancer Center, Cleveland

44195

RECRUITING

Cleveland Clinic Taussig Cancer Center, Cleveland

44718

RECRUITING

Gabrail Cancer & Research Center, Canton

48201

RECRUITING

The Barbara Ann Karmanos Cancer Institute, Detroit

63108

RECRUITING

Washington University, Siteman Cancer Center, St Louis

90033

RECRUITING

University of Southern California- Norris Cancer Center, Los Angeles

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

07960

RECRUITING

Atlantic Health System, Morristown